Investigating and addressing the immediate and long-term consequences of the COVID-19 pandemic on patients with substance use disorders: a scoping review and evidence map protocol.

Abstract

INTRODUCTION:

The COVID-19 pandemic has driven unprecedented social and economic reform in efforts to curb the impact of disease. Governments worldwide have legislated non-essential service shutdowns and adapted essential service provision in order to minimise face-to-face contact. We anticipate major consequences resulting from such policies, with marginalised populations expected to bear the greatest burden of such measures, especially those with substance use disorders (SUDs).

METHODS AND ANALYSIS:

We aim to conduct (1) a scoping review to summarise the available evidence evaluating the impact of the COVID-19 pandemic on patients with SUDs, and (2) an evidence map to visually plot and categorise the current available evidence evaluating the impact of COVID-19 on patients with SUDs to identify gaps in addressing high-risk populations.

ETHICS AND DISSEMINATION:

Ethics approval is not required for this scoping review as we plan to review publicly available data. This is part of a multistep project, whereby we intend to use the findings generated from this review in combination with data from an ongoing prospective cohort study our team is leading, encompassing over 2000 patients with SUDs receiving medication-assisted therapy in Ontario prior to and during the COVID-19 pandemic.

• Authors: Leen Naji, Brittany Dennis, Rebecca L Morgan, Nitika Sanger, Andrew Worster, James Paul, Lehana Thabane, Zainab Samaan
• Journal: BMJ open (BMJ Open) Vol. 11 Issue 9 Pg. e045946 (09 07 2021) ISSN: 2044-6055 [Electronic] England
• PMID: 34493506 (Publication Type: Journal Article, Review)
• Copyright: © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Chemical References

• Mitomycin
• Doxorubicin
• Cisplatin

Topics

• Antineoplastic Combined Chemotherapy Protocols
• COVID-19
• Cisplatin
• Doxorubicin
• Humans
• Mitomycin
• Pandemics
• Prospective Studies
• SARS-CoV-2
• Substance-Related Disorders (epidemiology)